Overview of the THERAKOS™ CELLEX™ Photopheresis System
THERAKOS™ is recognized as the sole fully integrated and validated Extracorporeal Photopheresis (ECP) system. Recently, it achieved a significant milestone by receiving the CE certificate under the revised European Union Medical Device Regulation (EU MDR). This achievement marks an important advancement in the safety and efficacy standards for medical devices.
Details on CE Certification
The CE Certification was awarded after a thorough process that included a detailed audit of the quality management system, technical reviews, microbiological assessments, and a comprehensive clinical evaluation. The EU MDR's stringent framework aims to promote medical innovation while ensuring patient safety is prioritized.
The Certification Journey
To secure the CE certification, the THERAKOS team submitted an application that highlighted several design improvements. Key enhancements included:
- Incorporating the anticoagulant ACD-A into the existing labeling.
- Making significant material changes to eliminate DEHP, in compliance with the latest RoHS standards to protect patient health.
Intended Use
The THERAKOS™ CELLEX™ Photopheresis System is specifically designed for patients over 18 who need photopheresis for the treatment of conditions such as:
- Cutaneous T Cell Lymphoma
- Solid Organ Transplant Rejection (particularly for heart and lung transplant patients)
For younger patients, the system is suitable for those over 3 years old who are experiencing:
- Acute and Chronic Graft versus Host Disease.
Leadership Insights
Christopher Hirt, MD, Vice President of Hospital International, shared his enthusiasm regarding the certification: "We are excited that THERAKOS has obtained the CE Certificate, which adheres to the enhanced safety and performance standards for medical devices in the EU. This accomplishment boosts healthcare providers' confidence in using THERAKOS for their patients."
About the THERAKOS™ CELLEX™ System
The THERAKOS CELLEX™ Photopheresis System represents a pinnacle of advanced therapeutic technology, performing ECP through patented techniques. This process isolates a small volume of white blood cells, treats them, and reinfuses them back into the patient, leveraging the benefits of immunomodulation to address various immune-mediated conditions. Currently, over 300 treatment centers in 30 countries utilize this innovative system.
Understanding Extracorporeal Photopheresis (ECP)
Extracorporeal Photopheresis (ECP) is a cutting-edge therapeutic approach that has demonstrated considerable potential in treating several immune-related disorders. This therapy is supported by a variety of international clinical guidelines that endorse its application for:
- Cutaneous T-cell lymphoma (CTCL)
- Acute and chronic graft-versus-host disease (aGvHD and cGvHD)
- Chronic lung allograft dysfunction
- Conditions following cardiac transplantation.
Safety Information and Precautions
While the THERAKOS™ CELLEX™ Photopheresis System offers significant benefits, it is crucial to be aware of the associated risks and contraindications:
Contraindications
- Patients with a history of light sensitivity.
- Individuals who cannot tolerate extracorporeal volume loss.
- Those with coagulation disorders or who have previously undergone splenectomy.
Warnings
- All treatments should occur in settings equipped for medical emergencies.
- Exposure of the device to magnetic resonance environments should be avoided to prevent potential injuries.
- Particular attention should be paid to anticoagulation during Graft versus Host Disease treatments to reduce the risk of thromboembolic events.
Methoxsalen and Its Role in Treatment
Methoxsalen is frequently used in conjunction with the THERAKOS™ Photopheresis procedure. However, it is essential to understand the contraindications and warnings related to methoxsalen:
- It is not recommended for patients with hypersensitivity to methoxsalen or similar compounds.
- Patients with certain skin cancers, those who are pregnant, and individuals who have undergone lens removal surgery should refrain from its use.
About Mallinckrodt
Mallinckrodt is a global leader in specialty pharmaceuticals, dedicated to developing and distributing products that address rare and complex conditions. The company focuses on various therapeutic areas, including neurology, oncology, and rheumatology, among others. To learn more about Mallinckrodt and its offerings, visit www.mallinckrodt.com.
Frequently Asked Questions
What is the THERAKOS™ CELLEX™ Photopheresis System?
The THERAKOS™ CELLEX™ Photopheresis System is a medical device designed for extracorporeal photopheresis, a therapy used to treat immune-mediated diseases.
Who can use the THERAKOS™ CELLEX™ System?
This system is intended for patients over 18 years old with specific conditions like Cutaneous T Cell Lymphoma, as well as for younger patients suffering from Graft versus Host Disease.
What are the key updates in the CE certification process?
The updated certification process included improved design features and stringent regulatory compliance measures to enhance both safety and performance.
What diseases can ECP therapy treat?
ECP therapy is indicated for conditions such as CTCL, graft-versus-host disease, and chronic lung allograft dysfunction.
How should Methoxsalen be used?
Methoxsalen should be administered with caution and is contraindicated for certain patient groups; it is important to be aware of its associated risks.
